Healthcare Global Enterprises Ltd Stock Price Today (NSE: HCG)
Fundamental Score
Healthcare Global Enterprises Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Healthcare Global Enterprises Ltd share price today is ₹525.20, down 0.75% on NSE/BSE as of 30 March 2026. Healthcare Global Enterprises Ltd (HCG) is a Mid-cap company in the Hospital sector with a market capitalisation of ₹10.47K (Cr). The 52-week high for HCG share price is ₹804.65 and the 52-week low is ₹501.25. At a P/E ratio of 296.22x, HCG is currently trading above its industry average P/E of 52.84x. The company has a Return on Equity (ROE) of 5.14% and a debt-to-equity ratio of 1.92.
Healthcare Global Enterprises Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Healthcare Global Enterprises Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Healthcare Global Enterprises Share Price: A Financial Stability Analysis
The hospital industry is undergoing a significant transformation, driven by technological advancements, increased regulatory scrutiny, and evolving patient expectations, putting pressure on even established players. This analysis focuses on the financial stability of Healthcare Global Enterprises Ltd (HCG), examining its current valuation and operational efficiency as reflected in the Healthcare Global Enterprises share price of ₹568.650024. Our evaluation considers key metrics like Price-to-Earnings (PE) ratio and Return on Capital Employed (ROCE), alongside a comparison with sector peers.
HCG currently trades at a PE ratio of 296.22. This high PE suggests that investors have high expectations for future earnings growth. However, it's crucial to assess whether this expectation is supported by the company's underlying performance. In contrast, observing management quality within peer group entities like
Nephro Care India Limited can reveal potential variations in operational excellence and capital allocation strategies, factors that significantly impact long-term shareholder value. A deeper dive into management decisions and their impact on strategic direction would provide further insight.A critical metric for evaluating HCG's financial stability is its ROCE, currently at 8.56%. ROCE measures how effectively a company generates profits from its capital employed. While a positive ROCE is encouraging, the magnitude of 8.56% needs to be benchmarked against industry averages and the company's cost of capital. A higher ROCE generally indicates a stronger competitive advantage or "moat". However, in HCG's case, this level of ROCE suggests that while the company is profitable, its ability to generate excess returns on invested capital may be somewhat constrained, potentially limiting its capacity to invest in future growth initiatives and strengthen its market position. Further analysis of HCG's operational efficiencies, cost structures, and revenue streams is vital to fully understand its ROCE performance.
This financial analysis of Healthcare Global Enterprises share price is part of a more comprehensive 80-parameter fundamental audit, verified by Sweta Mishra, aimed at providing a detailed observational view of the company's financial health and long-term prospects. It is important to conduct further research and consult with a qualified financial advisor before making any investment decisions. This analysis does not constitute a recommendation to buy or sell securities of Healthcare Global Enterprises Ltd.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Healthcare Global Enterprises Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of HCG across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Strong Operating Margins (16.59%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Strong Revenue Growth (16.86%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (15.22% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (17.79% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (19.34% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Strong Cash Generation (₹571.13 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (63.78%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Risk Factors
6 factors identified
Below-Average Return on Equity (5.14%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (8.56%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 296.22x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Elevated Debt Levels (D/E: 1.92)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Weak Interest Coverage (1.24x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Healthcare Global Enterprises Ltd Financial Statements
Comprehensive financial data for Healthcare Global Enterprises Ltd including income statement, balance sheet and cash flow
About HCG (Healthcare Global Enterprises Ltd)
Healthcare Global Enterprises Ltd is a leading institution redefining cancer care within its hospital settings. Stepping inside, one encounters a meticulously designed environment,... intended to foster healing and well-being. The advanced infrastructure houses cutting-edge diagnostic and treatment technologies, from high-resolution imaging suites to specialized operating theaters equipped for complex oncological procedures. A palpable sense of hope permeates the air, amplified by the presence of compassionate medical staff who prioritize patient comfort and understanding. The hospital's architecture emphasizes natural light and open spaces, aiming to minimize anxiety and create a welcoming atmosphere for patients and their families navigating challenging circumstances. Art installations and calming color palettes further contribute to a holistic approach that extends beyond mere physical treatment. Beyond the physical infrastructure, HCG hospitals are hubs of medical innovation and expertise. A multidisciplinary team of oncologists, surgeons, radiologists, and support staff collaborate seamlessly to deliver personalized treatment plans tailored to each patient's unique needs. Research and development are integral components of the hospital's ethos, driving the adoption of novel therapies and techniques. Regular training programs ensure that healthcare professionals stay at the forefront of oncological advancements. Emphasis is placed on precision medicine, utilizing advanced genomic testing and molecular diagnostics to optimize treatment effectiveness while minimizing side effects. This commitment to pioneering approaches positions HCG as a center of excellence in cancer care. The patient experience at HCG hospitals extends far beyond the confines of medical procedures. A comprehensive support system is in place to address the emotional, psychological, and social needs of individuals undergoing cancer treatment. Counseling services, support groups, and palliative care are readily available, fostering a sense of community and shared understanding. The hospital emphasizes open communication and patient empowerment, ensuring that individuals are actively involved in their care decisions. Furthermore, nutritional guidance, rehabilitation programs, and survivorship support are integrated into the treatment journey, promoting long-term well-being and improving the quality of life for patients and their families.
Company Details
Key Leadership
HCG Share Price: Frequently Asked Questions
What is the current share price of Healthcare Global Enterprises Ltd (HCG)?
As of 30 Mar 2026, 12:06 pm IST, Healthcare Global Enterprises Ltd share price is ₹525.20. The HCG stock has a market capitalisation of ₹10.47K (Cr) on NSE/BSE.
Is HCG share price Overvalued or Undervalued?
HCG share price is currently trading at a P/E ratio of 296.22x, compared to the industry average of 52.84x. Based on this relative valuation, the Healthcare Global Enterprises Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of HCG share price?
The 52-week high of HCG share price is ₹804.65 and the 52-week low is ₹501.25. These values are updated daily from NSE/BSE price data.
What factors affect the Healthcare Global Enterprises Ltd share price?
Key factors influencing HCG share price include quarterly earnings growth (Sales Growth: 16.86%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Healthcare Global Enterprises Ltd a good stock for long-term investment?
Healthcare Global Enterprises Ltd shows a 5-year Profit Growth of 19.34% and an ROE of 5.14%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 1.92 before investing in HCG shares.
How does Healthcare Global Enterprises Ltd compare with its industry peers?
Healthcare Global Enterprises Ltd competes with major peers in the Hospital. Investors should compare HCG share price P/E of 296.22x and ROE of 5.14% against the industry averages to determine competitive standing.
What is the P/E ratio of HCG and what does it mean?
HCG share price has a P/E ratio of 296.22x compared to the industry average of 52.84x. Investors pay ₹296 for every ₹1 of annual earnings.
How is HCG performing according to Bull Run's analysis?
HCG has a Bull Run fundamental score of 36.4/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does HCG belong to?
HCG operates in the Hospital industry. This classification helps understand the competitive landscape and sector-specific trends affecting Healthcare Global Enterprises Ltd share price.
What is Return on Equity (ROE) and why is it important for HCG?
HCG has an ROE of 5.14%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Healthcare Global Enterprises Ltd generates profits from shareholders capital.
How is HCG debt-to-equity ratio and what does it indicate?
HCG has a debt-to-equity ratio of 1.92, which indicates high leverage that increases financial risk.
What is HCG dividend yield and is it a good dividend stock?
HCG offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Healthcare Global Enterprises Ltd shares.
How has HCG share price grown over the past 5 years?
HCG has achieved 5-year growth rates of: Sales Growth 15.22%, Profit Growth 19.34%, and EPS Growth 17.79%.
What is the promoter holding in HCG and why does it matter?
Promoters hold 63.78% of HCG shares, with 5.52% pledged. High promoter holding often indicates strong management confidence in Healthcare Global Enterprises Ltd.
What is HCG market capitalisation category?
HCG has a market capitalisation of ₹10474 crores, placing it in the Mid-cap category.
How volatile is HCG stock?
HCG has a beta of N/A. A beta > 1 suggests the Healthcare Global Enterprises Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is HCG operating profit margin trend?
HCG has a 5-year average Operating Profit Margin (OPM) of 16.59%, indicating the company's operational efficiency.
How is HCG quarterly performance?
Recent quarterly performance shows Healthcare Global Enterprises Ltd YoY Sales Growth of 16.86% and YoY Profit Growth of -9.56%.
What is the institutional holding pattern in HCG?
HCG has FII holding of 3.59% and DII holding of 18.36%. Significant institutional holding often suggests professional confidence in the Healthcare Global Enterprises Ltd stock.